Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.
  • Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment.
  • A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
  • Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves.

    Use of PRADAXA for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.

    Ef
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
    2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
    5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
    6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
    8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
    9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
    10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
    11. Boehringer Ingelheim Announces Equine Research Awards
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
    (Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
    (Date:3/26/2015)... 26, 2015 When they began experiencing ... PACS vendor their system would no longer be ... needed a better structured solution to support their ... due to its interface capabilities and its 2014 ... through to the hospital,s radiology department. Avreo,s experienced ...
    Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
    ... Great Neck, N.Y., Jan. 18 On January 17, ... Law Firm, LLC, Douglas & London,P.C., Levin Simes Kaiser ... Luxenberg, P.C., have filed over a Billion ($1,000,000,000) Dollar,Class ... Federal,District Court, Eastern District of New York, Docket #08-258 ...
    ... RIDGEFIELD, Conn., Jan. 17 Boehringer Ingelheim,announced ... landmark RE-LY trial to,evaluate the long-term efficacy ... dabigatran etexilate for the prevention of stroke ... RE-LY (Randomized,Evaluation of Long Term Anticoagulant Therapy) ...
    Cached Medicine Technology:Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study 2Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study 3Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study 4
    (Date:3/27/2015)... CA (PRWEB) March 27, 2015 Smile ... leading providers of business support services to dental groups ... of an affiliated Castle Dental office in ... Blvd. Hendersonville, TN 37075, this new Castle Dental office ... can receive the latest in comprehensive, quality dental care. ...
    (Date:3/27/2015)... In light of two lawsuits that ... District Court, District of Massachusetts; and case number 2:15-cv-00709PD, ... Pennsylvania), the San Diego personal injury lawyers of The ... that they are available to investigate potential birth ... prescribed Zofran while pregnant and who gave birth to ...
    (Date:3/26/2015)... 26, 2015 Dr. Rod J. ... Dallas Rhinoplasty Symposium and has trained over 6500 ... importance of evidence based medicine (EBM), that is, the ... conducted research. , "We often hear from rhinoplasty ... while we are certainly not trying to stifle these ...
    (Date:3/26/2015)... Florida Hospital teamed up with ABC Action ... campaign and live Dr. Oz event, which took place at ... than a thousand people came out to see Dr. Mehmet ... The world renowned cardiothoracic surgeon and Emmy award winning talk ... a panel of experts for the live health expo. Florida ...
    (Date:3/26/2015)... (PRWEB) March 26, 2015 Behavioral ... consulting firm, announced the release of BathroomMap® , ... to increase access to public restrooms for travelers, especially ... bathroom apps, BathroomMap does not facilitate a paid, social ... to identify and rate local establishments that have clean, ...
    Breaking Medicine News(10 mins):Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 2Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 3
    ... N.C. A new study published recently in The ... asthma medicines -- long-acting beta-agonists -- may not be ... genotype (gene variation), as previous studies had shown. ... therapy, used in combination with inhaled corticosteroids, in asthmatics ...
    ... is exquisitely tuned to discern different sound frequencies, whether such ... ability of our ears pales in comparison to the remarkable ... the very subtlest of sound frequencies. , Reporting in the ... a professor of neurosurgery and director of the epilepsy surgery ...
    ... Guide Highlights Health Care Fraud Investigations & ... NHCAA Mission to Protect and Serve the ... of Detection,Investigation, Civil and Criminal Prosecution and ... The National Health Care,Anti-Fraud Association (NHCAA) ...
    ... - Actress and musician joins Jenny Craig to relay the message of a ... ... Craig Inc., one of the,nation,s leading authorities on weight management, held a press ... the company,s newest celebrity client. The Oscar-nominated,singer and actress will be the focal ...
    ... health ... plan enrollment and compliance, PITTSBURGH, Jan. 10 ... care industry, has,developed a solution that benefits seniors and dramatically ... solutions to boost the bottom-line for health plans.,MedicareCRM will be ...
    ... Teams with Top Athletes to Teach Kids ... ... Asthma and Activity Actually Go Together, ... up,as top athletes get behind an innovative asthma awareness initiative ... Schaeffer, Breathe Easy Play Hard is rooted in a website, ...
    Cached Medicine News:Health News:Auditory neurons in humans far more sensitive to fine sound frequencies than most mammals 2Health News:Auditory neurons in humans far more sensitive to fine sound frequencies than most mammals 3Health News:NHCAA Releases 'Fraud Fighters Handbook' Outlining Strategies to Protect the Public Against Health Care Fraud 2Health News:Queen Latifah Brings in the New Year with a Healthy Resolution 2Health News:MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries 2Health News:MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries 3Health News:'Breathe Easy. Play Hard.' 2
    The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
    ... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
    ... ONE™ technology is the first ... a patented digital sensor ... analog sensor. Dolphin ONE™ sensors ... signal in the sensor, resulting ...
    ... Immersion Oil is a clear, colorless ... most of the UV-VIS spectrum. Resolve ... high viscosity, is non-drying and non-hardening, ... 1.5150. Resolve contains no PCBs, eliminating ...
    Medicine Products: